Drug profile · INN
pasireotide pamoate
SIGNIFOR PARTIAL CHANGE APPROVAL
pasireotide pamoate (SIGNIFOR PARTIAL CHANGE APPROVAL) is a somatostatin receptor 2 agonist. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — pasireotide pamoate
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pasireotide pamoate (SIGNIFOR PARTIAL CHANGE APPROVAL) is a somatostatin receptor 2 agonist. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
Somatostatin receptor 2 agonist
Primary target: Somatostatin receptor type 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pasireotide pamoate?
pasireotide pamoate (SIGNIFOR PARTIAL CHANGE APPROVAL) is a somatostatin receptor 2 agonist. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for pasireotide pamoate?
SIGNIFOR PARTIAL CHANGE APPROVAL is a marketed brand name for pasireotide pamoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pasireotide pamoate?
pasireotide pamoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.